Zarella Returns To Bausch & Lomb Driver’s Seat After Stint With GM
This article was originally published in The Gray Sheet
Executive Summary
Among the initial tasks facing incoming Bausch & Lomb Chairman and CEO Ronald Zarella is to revive sagging revenues across four of the company's five operating divisions and generate interest in the ophthalmic products firm once again on Wall Street
You may also be interested in...
Financings In Brief
Alliance Medical: Initial public offering will await FDA clearance of five additional 510(k) submissions for reprocessed disposable medical devices, the firm said. The Phoenix company, which has already received clearances for 15 out of 20 510(k)s submitted to the agency, withdrew its August 2001 IPO registration statement March 15. "We feel that conditions for raising money from the public market will be better after FDA has acted on our remaining 510(k) submissions," Alliance explained in a release...
B&L Relying On PureVision Growth To Offset Refractive Market Decline
Bausch & Lomb says it is counting on product introductions that incorporate new technologies, such as the PureVision continuous-wear lenses, to offset lagging sales of older lines as the firm works to stabilize its financial performance
B&L Relying On PureVision Growth To Offset Refractive Market Decline
Bausch & Lomb says it is counting on product introductions that incorporate new technologies, such as the PureVision continuous-wear lenses, to offset lagging sales of older lines as the firm works to stabilize its financial performance